Phase 3
N=36
Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients
Varicella
Bottom Line
View on ClinicalTrials.gov: NCT00127608 ↗Enrolled (actual)
36
Serious AEs
—
Results posted
Feb 2019
Primary outcome: Primary: Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample — 6.49; 6.46; 6.07; 6.02 VZV genome copies per sample
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Collection of clinical samples (Procedure)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- GlaxoSmithKline
- Primary completion
- Jul 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample |
6.49; 6.46; 6.07; 6.02; 6.98; 6.98 | — |
| PRIMARY Viral Load: Number of Varicella Zoster Virus (VZV) Deoxyribonucleic Acid (DNA) Copies Per Clinical Sample by Storage Condition (Dry, Liquid) |
6.34; 6.82 | <0.0001 sig |
| PRIMARY Estimated Mean Viral Load (in log10) by Sample Types (Papule Swab, Vesicle Fluid and Vesicle Swab) |
6.29; 6.74; 6.72 | 0.0038 sig |
Summary
This study is conducted in order to collect clinical samples from patients who are diagnosed of having chickenpox infection. The results of this study will provide basic scientific information about chickenpox disease.
Eligibility Criteria
Pediatric patients who are diagnosed of having varicella and are presenting varicella dermal lesions.
Data sourced from ClinicalTrials.gov (NCT00127608). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.